AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02356276
Drug: Systemic chemotherapy (XELOX or SOX regimens)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELOX regimen: Oxaliplatin: 130 mg/m\^2, IV, d1; Capecitabine: 1 g/m\^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.~SOX regimen: Oxaliplatin: 130 mg/m\^2, IV, d1; S-1, 40 mg/m\^2 bid, po, day 1-14 (S-1: BSA \<1.25m\^2, 40mg bid, 1.25m\^2≤ BSA ≤1.5m\^2, 50mg bid, BSA\>1.5m\^2, 60 mg bid) bid, d1-14, po, every 3 weeks for a total of 6-8 cycles.
Trial: NCT03938454
Drug: Crizanlizumab
RxNorm normalized name: Crizanlizumab
DrugBank: Crizanlizumab (DB15271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crizanlizumab is a concentrate for solution for infusion, IV use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab.
Trial: NCT03864029
Drug: KUVAN
RxNorm normalized name: Kuvan
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: retrospective data on the effectiveness of past treatment with KUVAN®. It includes blood Phe level, physical development status, intelligence development status, etc., during treatment with KUVAN
Trial: NCT00717574
Drug: Sevoflurane group
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Addition of 60% nitrous oxide for 20 minutes duration, then back to 1:1 oxygen/air mixture.
Trial: NCT01110889
Drug: Agomelatine (AGO178C)
DrugBank: Agomelatine (DB06594)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT00717574
Drug: Propofol group
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Addition of 60% nitrous oxide for 20 minutes duration, then back to 1:1 oxygen/air mixture.
Trial: NCT03137173
Drug: ceftobiprole medocaril
RxNorm normalized name: Ceftobiprole medocaril
DrugBank: Ceftobiprole medocaril (DB14733)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ceftobiprole 500 mg was to be administered every 8 hours as a 2-hour IV infusion (with dose adjustment for renal impairment). The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.
Trial: NCT00005984
Drug: filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: filgrastim (G-CSF) daily subcutaneously (SQ) starting on day 5 and continuing until completion of leukapheresis. Patients also receive G-CSF IV starting on day 0 and continuing until blood counts recover
Trial: NCT00005984
Drug: recombinant interferon alfa
RxNorm normalized name: INTERFERON ALFA-2A,RECOMBINANT
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beginning on Day 1, subcutaneous (SQ) daily administration in the absence of unacceptable toxicity or disease progression
Trial: NCT03137173
Drug: vancomycin+aztreonam
RxNorm normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin 1000 mg (or 15 mg/kg) was to be administered every 12 hours (with dose adjustment for renal impairment) as 2-hour IV infusion. Vancomycin dose adjustment for morbidly obese and hypermetabolic patients was to be done according to local standard of care. When locally available, vancomycin trough testing (VTT) might have been used by the unblinded pharmacist or delegate to adjust the vancomycin dose. The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.~Aztreonam 1000 mg was to be administered as a 0.5-hour IV infusion every 12 hours. If CLCR was \< 30 mL/min (i.e., severe renal impairment), the aztreonam dosage regimen was to be adjusted. The requirement to continue aztreonam therapy beyond Day 3 was to be reassessed at the 72-hour study visit.
Trial: NCT02985827
Drug: Rohto (r) Hydra
RxNorm normalized name: Hydra-Neb
DrugBank: Hydroxyethyl cellulose (DB11602)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rohto (r) Hydra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose
Trial: NCT02985827
Drug: Systane (r) Ultra
RxNorm normalized name: pantolactone, (R)-
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systane (r) Ultra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose
Trial: NCT00668421
Drug: CEP-701 (Lestaurtinib)
RxNorm normalized name: CEP-9722
DrugBank: CEP-9722 (DB14882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lestaurtinib (CEP-701), oral formulation. Phase 1: 80 BID - 160 BID; phase 2: 140 mg
Trial: NCT04301375
Drug: Pertuzumab and trastuzumab FDC subcutaneous
RxNorm normalized name: hyaluronidase / pertuzumab / trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pertuzumab and trastuzumab FDC subcutaneous, A loading dose of 1200 mg pertuzumab and 600 mg trastuzumab followed by a maintenance dose of 600 mg pertuzumab and 600 mg; day 1 of each 3 week cycle during 5 neoadjuvant cycles and 13 adjuvant cycles if complete response
Trial: NCT04301375
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg/m2, day 1,8,15 of each 3 week cycle during 4 cycles
Trial: NCT04301375
Drug: TDM1
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3,6 mg/kg, 14 adjuvant cycles if not complete response
Trial: NCT01841281
Drug: L-Arginine
RxNorm normalized name: L-Arginine
DrugBank: L-arginine (DB17289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.
Trial: NCT01535638
Drug: BI 207127
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose film-coated tablet
Trial: NCT02053597
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All patients will receive four cycles paclitaxel (P) (200 mg/m2), given on a three-weekly basis for four cycles, followed by weekly paclitaxel (P) (80 mg/m2) for twelve weeks.
Trial: NCT00558961
Drug: Gleevec and Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The first cohort will receive Gleevec at 300 mg daily on days 1-10 and chlorambucil 8mg/m2/d from day 3-7. This will be repeated every 28 days. Cohort 2 will receive 400 mg Gleevec and Cohort 3 will receive 600 mg Gleevec. Each dose level may be expanded up to 6 patients if 1 of 3 patients experiences any dose limiting toxicities.
Trial: NCT00558142
Drug: Acetylcysteine
RxNorm normalized name: Acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive packs of either 8 placebo capsules or 8 acetylcysteine (600mg) capsules. They will be asked to take 2 tablets at 08.00 and 22.00 on the day before the study and the day of the study. On the day of the study participants will receive an IV infusion of either normal saline or acetylcysteine (200mg/kg)
Trial: NCT00558142
Drug: Visipaque 320
RxNorm normalized name: Visipaque 320mgI/mL Bulk Solution for Injection
DrugBank: Iodixanol (DB01249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mls IV dose as single dose
Trial: NCT00558142
Drug: Visipaque 320
RxNorm normalized name: Visipaque 320mgI/mL Bulk Solution for Injection
DrugBank: Iodixanol (DB01249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dose of Visipaque will be administered by the consultant cardiologist performing the coronary angiography
Trial: NCT00248456
Drug: Calcipotriol plus betamethasone dipropionate ointment
RxNorm normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04049344
Drug: Decitabine; Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive Decitabine 10 mg/day for 5 consecutive days (d1-5) plus Oxaliplatin 75mg/m2 2-week-cycle (d6, d20) within 4 weeks. One cycle is defined as 4 weeks of treatment and total of 6 cycles are designed for patients.
Trial: NCT00966836
Drug: Pre-emptive strategy with valganciclovir plus everolimus
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Everolimus plus cyclosporine and prednisone will be used for maintenance immunosuppression
Trial: NCT00966836
Drug: Prophylaxis with valganciclovir plus everolimus
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive valganciclovir for 3 months after transplant. Everolimus plus reduced cyclosporine and prednisone will be used for maintenance immunosuppression
Trial: NCT01512485
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel Tablets 75 mg
Trial: NCT00777140
Drug: Deferoxamine
RxNorm normalized name: Deferoxamine
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous deferoxamine: bolus 10mg/Kg (initiated during thrombolytic infusion, iv tPA), followed by intravenous perfusion of 20/40/60mg/Kg during 72h. It's a dose-finding study with 3 different doses of deferoxamine, with 20 patients (15 active:5 placebo) in each step.~Bolus + 72h perfusion of saline solution for the placebo group.
Trial: NCT03809637
Drug: Pemetrexed, cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500mg/m2, Intravenous, Q 3weeks. Cisplatin 75mg/m2, Intravenous, Q 3weeks. Combination administration : up to 6cycles After 6 cycle, pemetrexed alone is administered.
Trial: NCT04013386
Drug: Aprepitant and Dexamethasone
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant capsule 80 mg and Dexamethasone 8 mg IVI
Trial: NCT04013386
Drug: Mirtazapine and Dexamethasone
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirtazapine tablet 30 mg and Dexamethasone 8 mg IVI
Trial: NCT04013386
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 8 mg IVI
Trial: NCT05134337
Drug: LOXO-305
RxNorm normalized name: Loxoprofene
DrugBank: Loxoprofen (DB09212)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral LOXO-305
Trial: NCT05134337
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral itraconazole
Trial: NCT05134337
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rifampin
Trial: NCT00431990
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cohort 1 and 2A. 3.5mg/m2, IV, day 1, 4, 8, 11 in 28 day cycle. Cohort 2B. 3.5mg/m2, IV, day 1, 4, 8, 11 in 21 day cycle
Trial: NCT00431990
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20mg for 2 days with each dose of bortezomib
Trial: NCT02946437
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postconditioning with sevoflurane (0.5-1.5vol%) for 4 hours after coiling or clipping of cerebral aneurysm in patients with severe SAH
Trial: NCT02946437
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before and after postconditioning with sevoflurane the patients will be sedated with intravenous sedatives (midazolam or propofol). The quality of sedation before the postconditioning (propofol or midazolam) will be compared to the sedation one hour after starting the postconditioning (sevoflurane) in the same patient.
Trial: NCT02946437
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Before and after postconditioning with sevoflurane the patients will be sedated with intravenous sedatives (midazolam or propofol). The quality of sedation before the postconditioning (propofol or midazolam) will be compared to the sedation one hour after starting the postconditioning (sevoflurane) in the same patient.
Trial: NCT00132743
Drug: Cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol, 100 mg twice a day
Trial: NCT03059940
Drug: Nicotine Patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine patch dispensed. Dosing at physician's discretion.
Trial: NCT01657864
Drug: Lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder
Trial: NCT01531244
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given via ILI
Trial: NCT04184466
Drug: Insulin Aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: insulin aspart in doses 0.3 IU/kg
Trial: NCT03820596
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of refractory and relapsed ENKTCL patients, and to determine the MTD, DLT/RP2D of chidamide.~To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of refractory and relapsed ENKTCL patients. Exploring biomarkers that may have predictive effects.
Trial: NCT03820596
Drug: Chidamide
RxNorm normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of refractory and relapsed ENKTCL patients, and to determine the MTD, DLT/RP2D of chidamide.~To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of refractory and relapsed ENKTCL patients. Exploring biomarkers that may have predictive effects.
Trial: NCT01015066
Drug: Buprenorphine/naloxone
RxNorm normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sublingual tablets, 2/0.5mg (ratio buprenorphine:naloxone = 4:1), three times a day for six months (doses may be adjusted based on an individual's response)
Trial: NCT01015066
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tables, 50 mg/d, once a day for six months
Trial: NCT04226365
Drug: Nortriptyline
RxNorm normalized name: Nortriptyline
DrugBank: Nortriptyline (DB00540)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg capsule Nortryptyline
Trial: NCT01572597
Drug: 10RAC+acetylcystein
RxNorm normalized name: Acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + N-acetyl-cystein 600mg b.i.d
Trial: NCT01572597
Drug: 10RAC+metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + metronidazole 500mg b.i.d
Trial: NCT02537418
Drug: durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02537418
Drug: tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04164199
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously.
Trial: NCT01820299
Drug: Grape Seed Extract
RxNorm normalized name: Grape Seed Extract
DrugBank: Vitis vinifera seed (DB16606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients enrolled to the study will take Grape Seed Extract alone for 21 days.
Trial: NCT04164199
Drug: Pamiparib
RxNorm normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT01820299
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: From Day 22 until Day 64 of the study, patients will take Grape Seed Extract and Vitamin D together. Patients will take Vitamin D once at a day at 4000 IU.
Trial: NCT04164199
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally.
Trial: NCT04164199
Drug: Sitravatinib
RxNorm normalized name: Sitravatinib
DrugBank: Sitravatinib (DB15036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04164199
Drug: Ociperlimab
RxNorm normalized name: Ociperlimab
DrugBank: Ociperlimab (DB18947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously.
Trial: NCT04164199
Drug: Fruquintinib
RxNorm normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04164199
Drug: BGB-15025
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04164199
Drug: Zanidatamab
RxNorm normalized name: Zanidatamab
DrugBank: Zanidatamab (DB15471)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously.
Trial: NCT04164199
Drug: BGB-A445
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously.
Trial: NCT04164199
Drug: Surzebiclimab
RxNorm normalized name: Surzebiclimab
DrugBank: Surzebiclimab (DB16669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously.
Trial: NCT04164199
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally.
Trial: NCT01397331
Drug: Isoflurane
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia based on inhalation of 1-1.5 Minimal Alveolar Concentration of Isoflurane with the addition of infusion of remifentanil
Trial: NCT04006041
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received toripalimab 240 mg IVDRIP on days 1 and 22 during neoadjuvant radiotherapy.
Trial: NCT04006041
Drug: Paclitaxel/cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received 4 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22 during neoadjuvant radiotherapy.
Trial: NCT01397331
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia based on the infusion of 2-5 mg/kg/h of propofol with the addition of infusion of remifentanil
Trial: NCT02822274
Drug: Coppertone (BAY987517)
DrugBank: Copper (DB09130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-70_R84-064)
Trial: NCT01365468
Drug: Everolimus (RAD001)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral daily dosing of tablet starting with 2.5 mg
Trial: NCT03291067
Drug: MT-8554 1mg
RxNorm normalized name: lipase
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT-8554 1mg QD, oral, 12 weeks
Trial: NCT03291067
Drug: MT-8554 5mg
RxNorm normalized name: lipase
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT-8554 5mg QD, oral, 12 weeks
Trial: NCT03291067
Drug: MT-8554 10mg
RxNorm normalized name: lipase
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT-8554 10mg QD, oral, 12 weeks
Trial: NCT01109264
Drug: Bendamustine hydrochloride injection
RxNorm normalized name: bendamustine hydrochloride Injection
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: d1-2, i.v.gtt, 100mg/m2, 28 days per cycle, at most 6 cycles
Trial: NCT01109264
Drug: Chlorambucil
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: d1-d2, d15-d16, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles
Trial: NCT01941511
Drug: Rivipansel
RxNorm normalized name: Rivipansel
DrugBank: Rivipansel (DB12778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive in a randomized sequence rivipansel 4gA IV, moxifloxacin 400 mg, and placebo IV.
Trial: NCT00006242
Drug: BMS-214662
RxNorm normalized name: BMS-214662
DrugBank: BMS-214662 (DB12234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00982111
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 milligram per square meter (mg/m2) administered Intravenously (I.V.) on Day 1 of every 3-week cycle, for a maximum of six cycles
Trial: NCT00982111
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 administered I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles